Form 4: BioXcel Therapeutics Executive Javier Rodriguez Reports Stock Sales
SEC Form 4
Javier Rodriguez, Chief Legal Officer, Senior Vice President, and Corporate Secretary of BioXcel Therapeutics, Inc., reports the sale of common stock and vesting of restricted stock units.
Summary
- Javier Rodriguez, an officer at BioXcel Therapeutics, Inc., filed a Form 4 detailing changes in beneficial ownership.
- The report indicates the vesting of 521 and 563 Restricted Stock Units (RSUs) on September 14 and 15, 2024, respectively, which convert into common stock.
- Rodriguez also sold 345 shares of common stock on September 16, 2024, at a price of $0.69 per share.
- These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 14, 2023.
- Following these transactions, Rodriguez directly owns 9,133 shares of BioXcel Therapeutics, Inc.
- He also holds 3,127 and 5,625 Restricted Stock Units from grants in March 2022 and March 2023 respectively.
Sentiment
Score: 5
Explanation: Form 4 filings are factual reports of transactions; the sentiment is neutral unless the transaction pattern suggests a specific trend.
Industry Context
Form 4 filings are a routine part of the US stock market, providing transparency into the transactions of company insiders. Investors often monitor these filings to gauge executive sentiment and potential future stock performance.
Stakeholder Impact
- Shareholders may interpret the stock sale as a lack of confidence or a need for personal liquidity by the executive.
Key Dates
| Date | Description |
|---|---|
| 2022-03-14 | Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter |
| 2023-03-15 | Reporting Person was granted 9,000 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter |
| 2023-12-14 | Date the Reporting Person adopted a Rule 10b5-1 trading plan |
| 2024-09-14 | Vesting of 521 Restricted Stock Units |
| 2024-09-15 | Vesting of 563 Restricted Stock Units |
| 2024-09-16 | Sale of 345 shares of common stock at $0.69 per share |
| 2024-09-17 | Date of Form 4 filing |
Keywords
Form 4, BioXcel Therapeutics, BTAI, Javier Rodriguez, Restricted Stock Units, Stock Sale, Beneficial Ownership, Rule 10b5-1
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.